Scandius' tibial fixation system:
This article was originally published in Clinica
Executive Summary
The US FDA has given Scandius BioMedical 510(k) clearance to market its TriTis tibial fixation system for soft tissue anterior cruciate ligament (ACL) reconstruction. The implant was developed to address the problem of fixation strength in the tibia where bone quality is softer, and stronger fixation is needed to hold a soft tissue graft in place, according to the Littleton, Massachusetts firm. The TriTis device is designed to provide improved tibial fixation with a locking device that will prevent implant motion and provide increased pull-out strength, the company said.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.